Ignite Creation Date:
2024-05-06 @ 1:07 PM
Last Modification Date:
2024-10-26 @ 1:09 PM
Study NCT ID:
NCT03944772
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-14
First Post:
2019-04-29
Brief Title:
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy ORCHARD
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Non-Small Cell Lung Cancer |
Keywords:
| Name | View |
|---|---|
| Non-small cell lung cancer | View |
| NSCLC | View |
| tSCLC | View |
| NEC | View |
| Phase II | View |
| Platform study | View |
| Biomarker-directed | View |
| Durvalumab | View |
| Osimertinib | View |
| Savolitinib | View |
| Selumetinib | View |
| Etoposide | View |
| Gefitinib | View |
| Necitumumab | View |
| Platinum-containing doublet | View |
| Pemetrexed | View |
| EGFR positive | View |
| Carboplatin | View |
| Alectinib | View |
| Selpercatinib | View |
| Cisplatin | View |
| TKI-resistant | View |
| MET amplification | View |
| MET exon 14 skipping | View |
| EGFR | View |
| EGFR C797X | View |
| EGFR G724X | View |
| EGFR L718X | View |
| EGFR exon 20 insertion | View |
| EGFR amplification | View |
| BRAF V600E | View |
| ALK rearrangement | View |
| RET rearrangement | View |
| ROS1 rearrangement | View |
| NTRK fusion | View |
| KRAS G12C | View |
| Datopotamab deruxtecan | View |